Oppenheimer reiterates Procept BioRobotics stock rating

PROCEPT BioRobotics reported Q2 revenue of $94.5 million, up 19% year over year and ahead of expectations, but U.S. procedure growth was softer than expected and adjusted EPS loss of $0.47 was slightly wider than the $0.46 forecast. The company reduced its U.S. procedure outlook, while Jefferies cut its price target to $20 from $25 and William Blair downgraded the stock to Market Perform after procedure volumes came in 6% below revised estimates. Oppenheimer maintained a Perform rating but became more constructive contingent on resolution of Aquablation procedure-time and handpiece-inventory issues; WATER-IV trial topline data are not expected until AUA 2027.

Analysis

PRCT’s investability turns on whether the procedure shortfall reflects temporary center onboarding friction or a more fundamental utilization problem. If handpiece inventory is rising faster than completed cases, reported capital-equipment revenue can remain resilient while recurring consumables revenue, gross-margin absorption, and forward growth estimates deteriorate. That dynamic would justify further multiple compression because the market has historically valued PRCT on installed-base utilization rather than system placements alone.

The prostate-cancer opportunity should not provide near-term downside support: a pivotal readout several years away has limited value while execution metrics are weakening today, particularly if longer procedure times constrain operating-room throughput and hospital willingness to expand adoption. Intuitive Surgical (ISRG) is the relevant competitive benchmark; its entrenched surgeon base, workflow familiarity, and service infrastructure raise the bar for PRCT to prove that clinical advantages translate into economical use. The non-obvious risk is that hospitals may retain Aquablation systems but ration cases to ideal patients, depressing consumable pull-through without creating visible system churn.

Consensus may be too focused on the headline revenue growth rate and too willing to treat inventory normalization as mechanical. The key 1-3 month catalyst is the next quarterly disclosure of U.S. procedure growth, handpiece inventory days, installed-base additions, and utilization per system; improvement across all four could drive a sharp relief rally from a depressed base. Conversely, another procedure miss or reduced procedure outlook would signal that the issue is demand and workflow, not distribution timing, creating a 6-18 month reset in revenue and cash-burn expectations.

Key Decisions for Investors

• Maintain no new directional PRCT long until the next earnings release confirms procedure growth reacceleration and stable-to-lower handpiece inventory days; a revenue beat driven primarily by systems or upgrades is not sufficient confirmation.
• For healthcare growth exposure, favor a relative long ISRG / short PRCT pair over the next 1-3 months, sized modestly: ISRG should be more insulated if hospitals prioritize proven robotic workflow economics, while PRCT remains exposed to utilization revisions. Cover the short if PRCT reports procedure growth above guidance with sequential inventory normalization.
• Set a downside alert on PRCT for another full-year procedure-guide reduction or a second consecutive quarter of utilization below management’s installed-base assumptions; either would likely force further 2027 estimate cuts and challenge the current growth multiple.
• Do not underwrite the long-dated oncology trial as a near-term catalyst. Reassess only after independent evidence shows procedure duration can be reduced without compromising outcomes; absent that, the trial’s clinical promise may not translate into hospital-level return on investment.